Shots:
- Merck KGaA has entered into a definitive agreement to acquire SpringWorks Therapeutics to strengthen its rare disease portfolio & expand SpringWorks’ reach to markets beyond the US
- As per the agreement, Merck KGaA will acquire SpringWorks for $47/share (~26% premium), with an equity value of ~$3.9B or an enterprise value of ~$3.4B, funded by available cash & new debt, with closing expected in H2’25
- Additionally, SpringWorks’ Gomekli (mirdametinib) MAA for NF1-PN pts (≥2yrs.) is under EMA review, with potential approval in 2025, while the MAA for Ogsiveo (nirogacestat) in progressing desmoid tumors is also under EMA review, with a CHMP opinion expected in Q2’25
Ref: Merck KGAA | Image: SpringWorks Therapeutics
Related News:- SpringWorks Therapeutics Receives the US FDA Approval for Ogsiveo (nirogacestat) for the Treatment of Desmoid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
